NCT07204340View on ClinicalTrials.gov

TLN-372 in Advanced KRAS Mutant Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

240

Participants

Timeline

Start Date

October 9, 2025

Primary Completion Date

December 3, 2031

Study Completion Date

April 1, 2032

Conditions
KRAS Mutant Solid Tumors
Interventions
DRUG

TLN-372

Specified dose on specified days

DRUG

TLN-372 in combination with cetuximab

Specified dose on specified days

DRUG

TLN-372 in combination with pembrolizumab

Specified dose on specified days

Trial Locations (3)

6009

NOT_YET_RECRUITING

Linear Clinical Research, Perth

49546

RECRUITING

START Midwest, Grand Rapids

Unknown

NOT_YET_RECRUITING

Peter MacCallum Cancer Centre, Melbourne

All Listed Sponsors
lead

Treeline Biosciences, Inc.

INDUSTRY

NCT07204340 - TLN-372 in Advanced KRAS Mutant Solid Tumors | Biotech Hunter | Biotech Hunter